CMMB NASDAQ
Chemomab Therapeutics Ltd.
1W: -33.8%
1M: -47.6%
3M: -40.4%
YTD: -20.1%
1Y: -45.8%
3Y: -60.7%
5Y: -97.0%
$1.43
+0.13 (+10.00%)
Weekly Expected Move ±20.2%
$1
$1
$1
$2
$2
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Income Trends
Revenue
$0
+0.0% ▲
Gross Profit
-$71K
-32.5% ▼
Operating Income
-$10M
+34.6% ▲
Net Income
-$9M
+35.0% ▲
EPS (Diluted)
$-1.42
+54.5% ▲
EBITDA
-$10M
+31.4% ▲
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% |
| Cost of Revenue | $34K | $58K | $67K | $53K | $71K |
| Gross Profit | -$34K | -$58K | -$67K | -$53K | -$71K |
| Gross Margin | — | — | — | — | — |
| R&D Expenses | $6M | $17M | $18M | $11K | $6M |
| SG&A Expenses | $6M | $12M | $7M | $3K | $4M |
| Operating Expenses | $12M | $29M | $25M | $15M | $10M |
| Operating Income | -$12M | -$29M | -$25M | -$15M | -$10M |
| Operating Margin | — | — | — | — | — |
| Interest Expense | $111K | $353K | $0 | $0 | $0 |
| Income Before Tax | -$12M | -$28M | -$24M | -$14M | -$9M |
| Tax Expense | $0 | -$534K | $0 | $0 | $0 |
| Net Income | -$12M | -$28M | -$24M | -$14M | -$9M |
| Net Margin | — | — | — | — | — |
| EPS (Diluted) | $-4.80 | $-9.68 | $-8.22 | $-3.12 | $-1.42 |
| EBITDA | -$12M | -$28M | -$25M | -$14M | -$10M |
| Shares Outstanding | 3M | 3M | 3M | 4M | 6M |